The report titled ‘Global Follicular Lymphoma Treatment Market’ is a comprehensive report that offers detailed research and analysis of key aspects of the global Follicular Lymphoma Treatment market.

Follicular lymphoma (FL) is the second most frequent subtype of non-Hodgkin lymphoma, a cancer of the immune system. Although the disease is typically incurable, many cases progress slowly and do not ...

Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial Patients received induction ...

Interim Efficacy and Safety Data from Ongoing Phase 2 Study in Follicular Lymphoma and DLBCL Selected for Plenary Presentation at the International Conference on Malignant Lymphoma Management to Host ...

The FDA has granted Fast-Track designation to Xynomic Pharma's (OTCPK:XYNO) abexinostat, for use as a single agent, as a fourth-line treatment of relapsed or refractory follicular lymphoma (“FL”).

SAN DIEGO, March 31, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the U.S. Food ...

Follicular lymphoma is a slow-growing cancer that spreads through a person’s lymphatic system. Doctors may treat follicular lymphoma as they would a chronic condition, and the outlook is generally ...